Apolipoprotein B, usually shortened to ApoB, is a blood marker that estimates the number of cholesterol-carrying particles capable of entering artery walls and contributing to atherosclerosis.
LDL cholesterol measures how much cholesterol is being carried inside LDL particles. ApoB is closer to a count of the potentially harmful particles themselves. This distinction matters because two people with the same LDL cholesterol can have different numbers of particles—and potentially different levels of cardiovascular risk.
ApoB is not universally “better” than LDL cholesterol. For many people, ApoB, LDL cholesterol and non-HDL cholesterol tell a similar story. ApoB becomes particularly useful when the measurements disagree, especially in people with high triglycerides, type 2 diabetes, metabolic syndrome, obesity or cardiovascular disease despite apparently acceptable LDL cholesterol.
In the UK, standard cardiovascular assessment still usually relies on a full lipid profile, non-HDL cholesterol and an overall risk calculation. ApoB is generally an additional test rather than a replacement for these established measures.
This guide explains ApoB in general terms. A result should be interpreted alongside your complete lipid profile, blood pressure, smoking status, diabetes history, family history and any existing cardiovascular disease.
What is apolipoprotein B?
Lipids such as cholesterol and triglycerides cannot travel freely through blood. They are transported inside packages called lipoproteins.
Apolipoprotein B is a structural protein found on potentially atherogenic lipoprotein particles, including:
- low-density lipoprotein, or LDL;
- very-low-density lipoprotein, or VLDL;
- intermediate-density lipoprotein, or IDL;
- lipoprotein(a), usually written as Lp(a));
- remnant particles produced as triglyceride-rich lipoproteins are processed.
Each of these circulating atherogenic particles carries one main ApoB molecule. Measuring the concentration of ApoB therefore provides an estimate of how many potentially harmful particles are present.
This is different from measuring the total amount of cholesterol inside those particles. One person may have fewer cholesterol-rich particles, while another has a larger number of smaller particles carrying the same total quantity of cholesterol.
The more ApoB-containing particles circulating in the blood, the more opportunities there are for particles to enter and become retained within an artery wall. Over time, this can contribute to plaque formation, heart attack and ischaemic stroke.
Our complete guide to cardiovascular risk explains how cholesterol interacts with blood pressure, smoking, diabetes and other risk factors.
How is ApoB different from LDL cholesterol?
| Measurement | What it represents | Main limitation |
|---|---|---|
| LDL cholesterol | The amount of cholesterol carried mainly within LDL particles | Does not directly show how many particles are carrying it |
| Non-HDL cholesterol | Cholesterol in all non-HDL particles | Measures cholesterol content rather than particle number |
| ApoB | An estimate of the number of atherogenic lipoprotein particles | Not routinely measured or needed in every person |
| Lp(a) | The concentration of a genetically influenced lipoprotein | Assesses a specific inherited risk rather than total particle burden |
LDL cholesterol, written as LDL-C, answers the question: how much cholesterol is being carried in LDL?
ApoB answers a different question: approximately how many potentially atherogenic particles are circulating?
An analogy is to think of cholesterol as passengers and lipoproteins as vehicles. LDL-C estimates the number of passengers, whereas ApoB estimates the number of vehicles. Two roads can carry the same number of passengers but have very different numbers of vehicles.
That analogy is useful but imperfect. ApoB includes more than conventional LDL particles, and cardiovascular risk cannot be reduced to a single laboratory measurement.
See our guide to cholesterol test results for an explanation of total cholesterol, LDL, HDL, triglycerides and non-HDL cholesterol.
Is ApoB better than LDL cholesterol?
ApoB may represent atherosclerotic risk more accurately when the number of harmful particles does not match the quantity of cholesterol they contain. This situation is called discordance.
For example, a person may have:
- an LDL cholesterol result that appears reasonably controlled;
- a large number of relatively cholesterol-poor particles;
- a higher ApoB result than expected from the LDL cholesterol;
- more residual cardiovascular risk than LDL-C alone suggests.
When ApoB and LDL-C are broadly concordant, measuring ApoB may add relatively little to the clinical decision. When they are discordant, evidence indicates that risk tends to follow ApoB more closely.
This does not mean that LDL cholesterol is obsolete. LDL-C is widely available, strongly supported by clinical trials and familiar to clinicians. It remains central to diagnosing and treating high cholesterol.
ApoB is best viewed as a complementary marker that can refine the picture. A 2026 editorial in the European Journal of Preventive Cardiology explains that ApoB and non-HDL cholesterol can capture risk more comprehensively when they are disproportionately high relative to LDL-C.
Who may benefit from an ApoB blood test?
ApoB testing may be particularly informative when an ordinary lipid profile leaves uncertainty about cardiovascular risk or treatment response.
It may be worth discussing with a clinician if you have:
- high triglycerides;
- type 2 diabetes or prediabetes;
- central obesity or metabolic syndrome;
- very low LDL cholesterol while receiving intensive treatment;
- established coronary, cerebral or peripheral artery disease;
- a heart attack or stroke despite apparently acceptable LDL cholesterol;
- a strong family history of premature cardiovascular disease;
- a possible inherited lipid disorder;
- LDL cholesterol and non-HDL cholesterol results that seem inconsistent;
- uncertainty about whether lipid-lowering treatment is working sufficiently.
Discordance is more common when triglyceride-rich particles are present. People with insulin resistance may have a greater number of smaller, cholesterol-depleted LDL particles, allowing LDL-C to underestimate their atherogenic particle burden.
ApoB can also help monitor the overall effect of statins, ezetimibe, PCSK9-targeting medicines and other lipid-lowering treatments. However, UK prescribing decisions are generally not based on ApoB alone.
If diabetes is a possibility, read our guides to early signs of type 2 diabetes and diabetes blood-test results.
Who probably does not need ApoB testing?
Not everyone needs an advanced lipid marker. ApoB may add little when:
- you are at low overall cardiovascular risk;
- your standard lipid measurements are clearly normal and consistent;
- LDL-C, non-HDL cholesterol and triglycerides all point in the same direction;
- the result would not change any clinical decision;
- you already have a clear indication for lipid-lowering treatment;
- you are testing repeatedly without a defined monitoring plan.
A person who has already had a heart attack, stroke or another atherosclerotic event normally requires active risk reduction regardless of whether ApoB is measured.
Similarly, a very high LDL cholesterol or suspected familial hypercholesterolaemia should not be dismissed because ApoB has not been checked. Assessment and treatment should not be delayed while waiting for an optional additional marker.
A conventional lipid profile is inexpensive, widely standardised and sufficient for many people. Non-HDL cholesterol, which is usually calculated automatically, already captures cholesterol carried by LDL and other potentially harmful particles.
How do you interpret an ApoB result?
UK laboratories may report ApoB in grams per litre (g/L). Some international sources use milligrams per decilitre (mg/dL).
The conversion is straightforward:
- 0.60 g/L equals 60 mg/dL;
- 0.80 g/L equals 80 mg/dL;
- 1.00 g/L equals 100 mg/dL;
- 1.30 g/L equals 130 mg/dL.
A higher ApoB result generally indicates a larger number of atherogenic particles. However, there is no single cut-off that divides everyone into “safe” and “unsafe”.
The meaning depends on whether you are:
- otherwise healthy and at low short-term risk;
- at moderate or high calculated cardiovascular risk;
- living with diabetes or chronic kidney disease;
- known to have atherosclerotic cardiovascular disease;
- already taking cholesterol-lowering medication;
- being investigated for an inherited lipid condition.
European lipid guidance has used approximate ApoB treatment goals of:
| Cardiovascular-risk category | Example ApoB goal used in European guidance |
|---|---|
| Moderate risk | Below 1.00 g/L, or 100 mg/dL |
| High risk | Below 0.80 g/L, or 80 mg/dL |
| Very high risk | Below 0.65 g/L, or 65 mg/dL |
These are risk-based treatment goals rather than universal UK reference ranges. Laboratories and clinical guidelines may use different thresholds, and an isolated number should not be used to diagnose cardiovascular disease or change medication without medical advice.
A laboratory’s “normal range” is also not necessarily an ideal treatment target for someone who has already experienced a heart attack or stroke.
What does ApoB and LDL discordance mean?
Discordance means that ApoB and LDL-C sit in noticeably different positions relative to expected population levels.
Normal-looking LDL-C with higher ApoB
This pattern suggests that the cholesterol is distributed across a relatively large number of particles. Each particle may carry less cholesterol, but the particle count—and therefore the opportunity for particles to enter artery walls—is higher.
It is more commonly seen with:
- high triglycerides;
- insulin resistance;
- type 2 diabetes;
- abdominal obesity;
- metabolic syndrome.
In this situation, LDL cholesterol alone may underestimate risk.
Higher LDL-C with lower ApoB
This can occur when fewer particles each contain a relatively large amount of cholesterol. ApoB may indicate a lower particle burden than the LDL-C result initially implies.
However, it would be unsafe to conclude from this pattern alone that high LDL cholesterol can be ignored. Overall risk, family history, non-HDL cholesterol, treatment status and possible inherited conditions still matter.
Discordance is a reason for careful interpretation—not a reason to select whichever result appears more reassuring.
How does ApoB compare with non-HDL cholesterol and Lp(a)?
Non-HDL cholesterol
Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. It includes cholesterol contained in LDL, VLDL, IDL, remnant particles and Lp(a).
It is useful because it:
- comes from an ordinary lipid profile;
- does not require a separate laboratory test;
- captures more atherogenic cholesterol than LDL-C alone;
- works well when triglycerides are raised;
- is used in UK treatment monitoring.
Non-HDL cholesterol measures the cholesterol carried in harmful particles, whereas ApoB estimates their number. The two usually correlate closely, although ApoB may provide additional information when particle composition is unusual.
NICE guidance on cardiovascular-risk assessment and lipid modification uses non-HDL cholesterol extensively. For primary prevention, NICE recommends aiming for a reduction of more than 40% in non-HDL cholesterol after starting lipid-lowering treatment.
Lipoprotein(a)
Lp(a) is a particular ApoB-containing particle whose concentration is largely determined by genetics. A high Lp(a) level can increase cardiovascular and aortic-valve risk independently of ordinary LDL cholesterol.
ApoB includes Lp(a) particles within the overall atherogenic particle count, but it does not reveal whether Lp(a) itself is unusually high. The two tests answer different questions.
Lp(a) is generally measured at least once rather than repeatedly because levels tend to remain relatively stable. ApoB may be repeated to monitor the effect of treatment.
ApoA1 and the ApoB-to-ApoA1 ratio
ApoA1 is the main structural protein on HDL particles. Some laboratories offer an ApoB-to-ApoA1 ratio, comparing atherogenic with predominantly protective lipoprotein systems.
This ratio has research and risk-prediction value, but it is not routinely required in ordinary UK cardiovascular assessment. Measuring ApoB alone alongside a full lipid profile is often easier to interpret.
How is the ApoB blood test performed?
ApoB is measured from a blood sample, usually taken from a vein in the arm. The test itself is no different from most routine blood tests.
Fasting is generally not essential for ApoB. However, your clinician or laboratory may request fasting when ApoB is being checked alongside triglycerides, glucose or other measurements affected by recent food intake.
Before the test, tell the clinician about:
- statins and other lipid-lowering medicines;
- recent major illness or surgery;
- pregnancy;
- substantial recent weight change;
- changes to diet or alcohol intake;
- diabetes, thyroid, liver or kidney conditions.
Acute illness can temporarily alter lipid measurements. If a surprising result was taken while you were unwell, the clinician may recommend repeating it after recovery.
Private ApoB testing is available through some UK clinics and laboratories. The fee may cover only the assay, with blood collection and clinical interpretation charged separately. Check whether the laboratory is appropriately accredited and whether a qualified clinician will review the complete result.
What happens if ApoB is high?
A high result does not require a special “ApoB treatment”. Management focuses on reducing the concentration of atherogenic particles and addressing total cardiovascular risk.
The clinician may review:
- the complete lipid profile;
- blood pressure;
- smoking;
- HbA1c or blood glucose;
- weight and waist measurement;
- kidney, liver and thyroid function;
- family history and premature cardiovascular disease;
- current medication and adherence;
- diet, alcohol and physical activity.
Depending on overall risk, the plan may include:
- reducing saturated fat and replacing it with unsaturated fats;
- increasing soluble fibre from foods such as oats, beans and lentils;
- regular physical activity;
- weight reduction where appropriate;
- stopping smoking;
- improving diabetes and blood-pressure control;
- starting or intensifying a statin;
- adding another lipid-lowering medicine when clinically indicated.
A lower-carbohydrate eating pattern may improve triglycerides in some people, but a diet high in saturated fat can raise LDL-C and ApoB. Changes that improve weight or glucose do not automatically improve every lipid marker.
Do not stop or alter a statin because of one privately obtained result. Our guide to statins, benefits and side effects explains how these medicines are used.
What are the limitations of ApoB testing?
ApoB is an informative marker, but it does not provide a complete cardiovascular assessment.
It cannot by itself show:
- whether plaque is already present in the arteries;
- where arterial disease is located;
- how stable or unstable a plaque may be;
- whether chest pain is caused by coronary disease;
- your future risk independently of age and other factors;
- whether a high particle count has a genetic or secondary cause;
- the individual contribution from Lp(a).
ApoB can also be falsely reassuring if someone focuses on it while ignoring high blood pressure, smoking, diabetes or symptoms requiring medical assessment.
In the UK, tools such as QRISK are used to estimate a person’s overall probability of a heart attack or stroke. ApoB is not a substitute for an appropriate clinical risk assessment.
If you have chest pressure, pain spreading to the arm or jaw, severe breathlessness, sweating, nausea or symptoms suggesting a heart attack, call 999. Do not wait for cholesterol or ApoB testing.
Frequently asked questions
What does an ApoB blood test measure?
It measures the concentration of apolipoprotein B, providing an estimate of the number of LDL, VLDL, IDL, remnant and Lp(a) particles capable of contributing to atherosclerosis.
Is ApoB the same as LDL cholesterol?
No. LDL cholesterol measures the amount of cholesterol carried mainly in LDL particles. ApoB estimates the number of atherogenic particles.
Is ApoB more accurate than LDL?
ApoB may predict risk more accurately when it is discordant with LDL-C, particularly in people with high triglycerides, diabetes, obesity or metabolic syndrome. When the measurements agree, the additional benefit may be modest.
What is a good ApoB result?
There is no single ideal result for everyone. Lower targets are generally used for people at higher cardiovascular risk. European guidance has used goals below 100 mg/dL for moderate risk, 80 mg/dL for high risk and 65 mg/dL for very high risk, but these are not universal reference ranges.
Is an ApoB of 100 mg/dL high?
It is equivalent to 1.00 g/L. Its significance depends on your cardiovascular-risk category, treatment status and other results. It may meet an approximate goal for someone at moderate risk but be above the desired level for a person at high or very high risk.
Do I need to fast for an ApoB test?
Usually not. Fasting may still be requested if other tests are being performed or if your clinician wants a fasting triglyceride measurement.
Can ApoB be high when LDL cholesterol is normal?
Yes. This can occur when cholesterol is carried in a large number of relatively small or cholesterol-poor particles. It is more common with high triglycerides, insulin resistance and type 2 diabetes.
Can LDL be high when ApoB is normal?
Yes. A smaller number of cholesterol-rich particles can produce this pattern. It still requires professional interpretation and does not automatically make a raised LDL-C harmless.
Does a standard cholesterol test include ApoB?
Usually not. A standard lipid profile generally includes total cholesterol, HDL cholesterol, triglycerides and calculated LDL and non-HDL cholesterol. ApoB normally has to be requested separately.
Is ApoB available on the NHS?
It can be requested in selected NHS settings, particularly specialist lipid services, but it is not routinely included in every cardiovascular check. Local availability and clinical criteria vary.
How often should ApoB be tested?
There is no need to test it frequently without a reason. It may be repeated after starting or changing treatment, often alongside the full lipid profile, once enough time has passed for the treatment to take effect.
Can diet lower ApoB?
Yes. Reducing saturated fat, increasing fibre, improving weight and controlling diabetes can reduce ApoB in some people. The size of the change varies, and medication may still be necessary when cardiovascular risk is high.
Should I test ApoB or Lp(a)?
They answer different questions. ApoB estimates total atherogenic particle burden, while Lp(a) identifies a specific largely inherited risk factor. A clinician may recommend either or both depending on your history.
Should ApoB replace my ordinary cholesterol test?
No. It is generally most useful when interpreted alongside total cholesterol, LDL-C, HDL-C, triglycerides and non-HDL cholesterol rather than used as a stand-alone replacement.
